AlphaGen Therapeutics Announces Completion of Series A Financing to Develop Novel Targeted Alpha Radioligand Therapies

SHANGHAI, China, August 7, 2025 – AlphaGen Therapeutics (“AlphaGen”), a biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative targeted radioligand therapies (RLTs), announced its completion of a Series A financing round, with participation from leading institutional investors.

The proceeds from this Series A funding round will accelerate the development of AlphaGen’s pipeline while further enhancing its radiopharmaceutical discovery capabilities and nationwide end-to-end supply chain, strengthening the company's position as a pioneer in targeted radioligand therapy innovation.

Founded in 2022 by seasoned investors with proven company formation expertise and joined by a world-class team of radiopharmaceutical specialists, AlphaGen has rapidly established a robust pipeline of next-generation Pb-212 based radiotherapies. Leveraging its differentiated target selection strategy and highly innovative Pb-212 R&D platform, the company has advanced multiple programs with FIC or BIC potentials into clinical/near clinical stage, including lead candidates that have generated promising human data in clinical trials. The company has built a fully integrated drug discovery and evaluation platform covering medicinal chemistry, radiolabeling, and in vitro/in vivo biological evaluation, enabling efficient pipeline development.

Through its exclusive cutting-edge AlphaDirect™ Pb-212 generator technology, Alphagen has successfully established China's first reliable and scalable supply of Pb-212 isotope. This breakthrough has allowed the company to develop a comprehensive radiopharmaceutical manufacturing system that covers the entire RLT production process from isotope generation, radiolabeling, hot drug preparation, and clinical supply. This fully integrated capability ensures the company to maintain full control over product quality and supply chain reliability. As the first Chinese company to build an end-to-end supply chain for Pb-212 based RLT, Alphagen has secured a critical competitive advantage in supporting the preclinical and clinical development of its pipeline.

About AlphaGen Therapeutics

AlphaGen Therapeutics is a radiopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative targeted radioligand therapies (RLTs). Leveraging its cutting-edge technology platform, the company aims to develop targeted RLTs for patients in China and around the world. For more information, please visit www.alphagentx.com and follow us on Wechat and LinkedIn.